DIA Pharmacovigilance and Risk Management Strategies Conference



Explore Insights

Hear from expert representatives in industry, regulatory, academia, and patient groups on how changes, updates, and new challenges in safety and risk management directly affect how the right products are getting to patients in a timely matter.

Engage

Not only will you learn from speakers and your colleagues during sessions, you will also have a myriad of opportunities to connect before, during, and after presentations end. There will be Round Table Luncheon Discussions, tabletop exhibits, and networking receptions to share experiences and discuss lessons learned.

The Future

New technologies and innovative methods in pharmacovigilance are coming to light, but do you know how to properly utilize them? This Conference focuses deeply on cutting edge innovation across the entire life cycle of biopharmaceutical products, including new therapeutic approaches to diseases that change patients' lives, enlightened evolution of regulatory science that speeds needed products to prescribers and patients, and, most importantly, engagement of patients in the product development and regulatory processes.

#PVRMS17

DIA Pharmacovigilance and Risk Management Strategies Conference

Short Courses

Course 1

Dive deeper into safety and risk management issues and solutions in the EU and US through **real-world experiences** from expert instructors during this full day course.

Course 2

The **PBRER** format, content, and analytical focus are accepted in many countries, including the US and Japan. Explore further how PBRER may make the pharmacovigilance enterprise **more efficient** in transferring value to patients.

Course 3

Professionals involved in the submission of postmarketing case safety reports to the **FAERS Database** will gain a deeper understanding of how to distinguish coding of medication errors, off-label use, intentional misuse, and product quality issues.

Course 4

If a government investigator knocks on your door today, **would your organization be ready for an inspection** of your pharmacovigilance system? Discuss FDA expectations and common missteps during the course, **FDA Pharmacovigilance Inspection Readiness**.

#PVRMS17

DIA